Secretome analysis of microarray data reveals extracellular events associated with proliferative potential in a cell line model of breast disease

Cancer Letters

Volumn 241, Issue 1, 2006, Pages 49-58

  Dombkowski, Alan A ^a   Cukovic, Daniela ^a   Novak, Raymond F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bioinformatics; Biomarker; Breast disease; Cancer; Microarray; Secretome

Indexed keywords

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 39049181954     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.008     Document Type: Article

References (38)

1. Russo J., Russo I.H. The pathway of neoplastic transformation of human breast epithelial cells. Radiat. Res. 2001, 155:151-154.
2. Abba M.C., Drake J.A., Hawkins K.A., Hu Y., Sun H., Notcovich C., et al. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 2004, 6:R499-R513.
3. Ye Y., Qiu T.H., Kavanaugh C., Green J.E. Molecular mechanisms of breast cancer progression: lessons from mouse mammary cancer models and gene expression profiling. Breast Dis. 2004, 19:69-82.
4. DeClerck Y.A., Mercurio A.M., Stack M.S., Chapman H.A., Zutter M.M., Muschel R.J., et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 2004, 164:1131-1139.
5. Li M., Lewis B., Capuco A.V., Laucirica R., Furth P.A. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 2000, 19:1010-1019.
6. Skrzydlewska E., Sulkowska M., Koda M., Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J. Gastroenterol. 2005, 11:1251-1266.
7. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5:29-41.
8. Schambony A., Kunz M., Gradl D. Cross-regulation of Wnt signaling and cell adhesion. Differentiation 2004, 72:307-318.
9. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat. Rev. Cancer 2003, 3:243-252.
10. Srivastava S., Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J. Nutr. 2002, 132:2471S-2475S.
11. Arun B., Hortobagyi G. Progress in breast cancer chemoprevention. Endocr. Relat. Cancer 2002, 9:15-32.
12. Manson M.M., Farmer P.B., Gescher A., Steward W.P. Innovative agents in cancer prevention. Recent Results Cancer Res. 2005, 166:257-275.
13. Cersosimo R.J. Tamoxifen for prevention of breast cancer. Ann. Pharmacother. 2003, 37:268-273.
14. Krishnamurthy S., Sneige N. Molecular and biologic markers of premalignant lesions of human breast. Adv. Anat. Pathol. 2002, 9:185-197.
15. Fabian C.J., Kimler B.F. Breast cancer chemoprevention: current challenges and a look toward the future. Clin. Breast Cancer 2002, 3:113-124.
16. Schnitt S.J. Benign breast disease and breast cancer risk: morphology and beyond. Am. J. Surg. Pathol. 2003, 27:836-841.
17. Dupont W., Page D. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 1985, 312:146-151.
18. Dawson P.J., Wolman S.R., Tait L., Heppner G.H., Miller F.R. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 1996, 148:313-319.
19. Miller F.R. Xenograft models of premalignant breast disease. J. Mammary Gland Biol. Neoplasia 2000, 5:379-391.
20. Starcevic S.L., Elferink C., Novak R.F. Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease. J. Natl Cancer Inst. 2001, 93:776-782.
21. Starcevic S.L., Diotte N.M., Zukowski K.L., Cameron M.J., Novak R.F. Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD). Toxicol. Sci. 2003, 75:74-81.
22. Clark G.J., Der C.J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. 1995, 35:133-144.
23. von Lintig F.C., Dreilinger A.D., Varki N.M., Wallace A.M., Casteel D.E., Boss G.R. Ras activation in human breast cancer. Breast Cancer Res. Treat. 2000, 62:51-62.
24. Eckert L.B., Repasky G.A., Ulku A.S., McFall A., Zhou H., Sartor C.I., et al. Involvement of ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 2004, 64:4585-4592.
25. Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J., et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003, 13:2265-2270.
26. Chen Y., Zhang Y., Yin Y., Gao G., Li S., Jiang Y., et al. SPD-a web-based secreted protein database. Nucleic Acids Res. 2004, 33:D169-D173.
27. Grimmond S.M., Miranda K.C., Yuan Z., Davis M.J., Hume D.A., Yagi K., et al. The mouse secretome: functional classification of the proteins secreted into the extracellular environment. Genome Res. 2003, 13:1350-1359.
28. Dombkowski A.A., Thibodeau B.J., Starcevic S.L., Novak R.F. Gene-specific dye bias in microarray reference designs. Fed. Eur. Biochem. Soc. Lett. 2004, 560:120-124.
29. Heyer L.J., Kruglyak S., Yooseph S. Exploring expression data: identification and analysis of coexpressed genes. Genome Res. 1999, 9:1106-1115.
30. Gene Ontology Consortium The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004, 32:D258-D261.
31. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
32. Yuen T., Wurmbach E., Pfeffer R.L., Ebersole B.J., Sealfon S.C. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res. 2002, 30:e48.
33. Talvensaari-Mattila A., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 2003, 89:1270-1275.
34. Leppa S., Saarto T., Vehmanen L., Blomqvist C., Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. 2004, 10:1057-1063.
35. Feldmann K.A., Pittelkow M.R., Roche P.C., Kumar R., Grande J.P. Expression of an immediate early gene, IEX-1, in human tissues. Histochem. Cell Biol. 2001, 115:489-497.
36. Wu M.X. Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis 2003, 8:11-18.
37. Kumar R., Lutz W., Frank E., Im H.-J. Immediate early gene X-1 interacts with proteins that modulate apoptosis. Biochem. Biophys. Res. Commun. 2004, 323:1293-1298.
38. Hu Y., Sun H., Drake J., Kittrell F., Abba M.C., Deng L., et al. From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res. 2004, 64:7748-7755.